|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Despite strict administrative regulations, the pharmaceutical sector is an increasingly competitive marketplace where established industry giants are vying against providers of cheaper, generic alternatives. Meanwhile, new companies – formed through merger and acquisition activities – are approaching the field.
Existing players are under increasing pressure. Delivering the highest quality products and accurate information on packaging is now more critical than ever before. Medications need to not only appeal to the consumer with clear guidelines on safe use, ingredients and side effects, but must also be compliant with the rigorous stateimposed standards.
Every package must contain accurate data and clear labelling before it can be distributed to healthcare and pharma organisations en masse. Given the unique regulations surrounding the sale of therapeutics and similar medical products compared to other goods, drug developers are required to take special care on their production lines, while keeping operational costs low.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Theravectys Announces $20M Funding Round
THERAVECTYS,
the world leading pioneer in lentiviral vector technology, announced
today a fully subscribed $20M funding round. This funding will be used
to progress the Theravectys pipeline by driving several vaccine
candidates, including their COVID vaccine, into phase 1 and 1-2 clinical
trials.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Emerging Markets: Goldmines or Landmines?
Pharm-Olam, LLC
Over the past decade, biopharmaceutical companies
have increasingly turned to emerging markets as a way
to reduce clinical trial costs and timelines. Areas such
as Eastern Europe, India, and Latin America—with their
ready population of treatment naïve patients—can be an
answer to the intense competition for patients seen in
developed markets. Many of the countries within these
regions may now be considered as “emerged” countries
but yet, conducting trials in these regions does require
some special attention and expertise. Before deciding to
conduct studies in these areas, companies should have a
full appreciation for the ethical, medical, regulatory, legal,
and operational hurdles that must be surmounted for
success. Here we highlight a number of those issues and
offer our recommendations for how sponsor companies
can deal with them effectively.
More info >> |
|
|
